Liquid Biopsy for Cancer: Review and Implications for the Radiologist
The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Imaging and image-guided procedures play an imperative role in the screening, diagnosis, and surveillance of cancer. Although emerging imaging techniques now enable more precise molecular characterization of tumors, multigenetic tumor profiling for targeted therapeutic selection remains limited to direct tissue acquisition. Even in the context of targeted therapy, tumors adapt to acquire resistance. This necessitates serial monitoring, traditionally through tissue acquisition, to identify the molecular mechanism of resistance and to guide second-line therapy. An alternative to tissue acquisition is the collection of circulating tumor markers such as cell-free nucleic acids and circulating tumor cells in the peripheral blood. This noninvasive diagnostic approach is referred to as the liquid biopsy. The liquid biopsy is currently used clinically for therapeutic guidance when tissue acquisition is impossible or when the specimen is inadequate. It is also being studied in the context of screening, diagnosis, and surveillance. As cancer treatment continues to move toward a focus on precision medicine, this developing technology may alter and/or augment the role of imaging in the management of cancer. This review aims to outline the use of liquid biopsy in cancer and its potential impact on diagnostic imaging and image-guided procedures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a highly sensitive liquid biopsy methodology, NGS-based ctDNA detection can enable the identification of tumor relapse earlier than traditional radiological examinations, thereby facilitating prompt treatment decisions.8, 9, 10”
From Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma (2024) · cites this paper as [8]
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,632
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
Research works printed but not linked: 4
- Hricak H, 2016, Radiology 2018, 286, 764
- Sabari JK, 2018, J Natl Cancer Inst
- Ferry-Galow KV, 2018, J Oncol Pract, JOP1800092
- Tempero MA, 1987, Cancer Res, 47, 5501
Cited by
Recent advancements in optical biosensors for cancer detection
Kaur, B., Kumar, S., & Kaushik, B. K. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113805 · Cited by 433
Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR
Monticciolo, D. L., Newell, M. S., Moy, L., Lee, C. S., & Destounis, S. V. (2023) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2023.04.002 · Cited by 290
Surface Plasmon Resonance (SPR) Sensor for Cancer Biomarker Detection
Das, S., Devireddy, R., & Gartia, M. R. (2023) · Biosensors · doi:10.3390/bios13030396 · Cited by 223
“Plasma, saliva, urine, serum, and blood can all be used to detect these components [63].”
BackgroundNovel Approaches to Screening for Breast Cancer
Mann, R. M., Hooley, R., Barr, R. G., & Moy, L. (2020) · Radiology · doi:10.1148/radiol.2020200172 · Cited by 167
Small extracellular vesicles in cancer
Abhange, K., Makler, A., Wen, Y., Ramnauth, N., Mao, W., Asghar, W., & Wan, Y. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.015 · Cited by 131
Do we still need breast cancer screening in the era of targeted therapies and precision medicine?
Trimboli, R. M., Rossi, P. G., Battisti, N. M. L., Cozzi, A., Magni, V., Zanardo, M., & Sardanelli, F. (2020) · Insights into Imaging · doi:10.1186/s13244-020-00905-3 · Cited by 66
“Finally, the availability of molecular analyses on liquid biopsy could represent another promising option [82, 83].”
BackgroundDarbandi, M. R., Darbandi, M., Darbandi, S., Bado, I., Hadizadeh, M. R., & Khorshid, H. R. K. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114227 · Cited by 58
A scoping review of factors influencing the implementation of liquid biopsy for cancer care
Sheriff, S., Saba, M., Patel, R., Fisher, G., Schroeder, T., Arnolda, G., Luo, D., Warburton, L., Gray, E. S., Long, G. V., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03322-w · Cited by 54
“Unlike traditional invasive procedures such as colonoscopies, mammograms and tissue biopsies [113, 114], LB offers less invasive alternatives for cancers such as brain and NSCLC cancer, which traditionally depend on more invasive techniques like cerebrospinal fluid and tissue biopsies [29, 115].”
Fluorescent carbon quantum dots for effective tumor diagnosis: A comprehensive review
Latha, B. D., Soumya, K., More, N., Choppadandi, M., Guduru, A. T., Singh, G., & Kapusetti, G. (2023) · Biomedical Engineering Advances · doi:10.1016/j.bea.2023.100072 · Cited by 54
Breast Cancer Screening and Diagnosis
Gegios, A. R., Peterson, M. S., & Fowler, A. M. (2023) · PET Clinics · doi:10.1016/j.cpet.2023.04.003 · Cited by 46
Microfluidic preparation of optical sensors for biomedical applications
Wang, Q., Wang, C., Yang, X., Wang, J., Zhang, Z., & Shang, L. (2023) · Smart Medicine · doi:10.1002/smmd.20220027 · Cited by 46
Yasamineh, S., Nikben, N., Ahmed, M. H., Kareem, R. A., Al-Aridhy, A. K., & Hooshiar, M. H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03379-1 · Cited by 44
“These materials may be taken from body fluids such as blood, saliva, urine, and serum [235].”
BackgroundSingh, S., Miglione, A., Raucci, A., Numan, A., & Cinti, S. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117050 · Cited by 41
Salivary Biomarkers in Lung Cancer
Skallevold, H. E., Vallenari, E. M., & Sapkota, D. (2021) · Mediators of Inflammation · doi:10.1155/2021/6019791 · Cited by 43
“Although bodily fl uids, such as blood, serum, urine, and sputum, have been extensively examined as liquid biopsy for diagnostic, prognostic, and predictive markers in LC, limited data exist on saliva as a potential liquid biopsy in LC [29].”
Fu, Y., Xu, Y., Liu, W., Zhang, J., Wang, F., Jian, Q., Huang, G., Zou, C., Xie, X., Kim, A. H., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102697 · Cited by 37
Cancer and Disease Diagnosis - Biosensor as Potential Diagnostic Tool for Biomarker Detection
Chaudhry, G.-E.-S., Akim, A. M., Safdar, N., Yasmin, A., Begum, S., Sung, Y. Y., & Muhammad, T. S. T. (2022) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/japtr.japtr_106_22 · Cited by 38
Liquid Biopsies: Emerging role and clinical applications in solid tumours
Sisodiya, S., Kasherwal, V., Khan, A., Roy, B., Goel, A., Kumar, S., Arif, N., Tanwar, P., & Hussain, S. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101716 · Cited by 37
Liquid biopsy for precision diagnostics and therapeutics
Anitha, K., Posinasetty, B., Kumari, K. N., Chenchula, S., Padmavathi, R., Prakash, S., & Chikatipalli, R. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117746 · Cited by 37
Wang, M., Wang, Y., Tian, X., Wang, Q., Huang, H., Lu, X., Qi, M., Cao, X., & Lei, J. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2195552 · Cited by 32
Ahmad, M. R. S., Hasan, M., Tarannum, N., Hasan, M., & Ahmed, S. (2023) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2023.100375 · Cited by 30
Adam‐Artigues, A., Garrido‐Cano, I., Carbonell‐Asins, J. A., Lameirinhas, A., Simón, S., Ortega-Morillo, B., Martínez, M. T., Hernándo, C., Constâncio, V., Burgués, O., et al. (2021) · Cancers · doi:10.3390/cancers13112848 · Cited by 28
Exploiting proteases for cancer theranostic through molecular imaging and drug delivery
Mumtaz, T., Qindeel, M., Rehman, A. U., Tarhini, M., Ahmed, N., & Elaïssari, A. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119712 · Cited by 24
Nakayama, T., Sano, T., Oshimo, Y., Kawada, C., Kasai, M., Yamamoto, S., Fukuhara, H., Inoue, K., & Ogura, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-86886-9 · Cited by 24
From Wilms to kidney tumors: which ones require a biopsy?
Brisse, H. J., de la Monneraye, Y., Cardoen, L., & Schleiermacher, G. (2020) · Pediatric Radiology · doi:10.1007/s00247-020-04660-x · Cited by 22
Sequence-Based Platforms for Discovering Biomarkers in Liquid Biopsy of Non-Small-Cell Lung Cancer
Brockley, L. J., Souza, V. G. P., Forder, A., Pewarchuk, M. E., Erkan, M., Telkar, N., Benard, K., Trejo, J., Stewart, M. D., Stewart, G. L., et al. (2023) · Cancers · doi:10.3390/cancers15082275 · Cited by 27
Hole, A. R., Jadhav, P. A., Pansare, K., Noothalapati, H., Deshmukh, A., Gota, V. S., Chaturvedi, P., & Krishna, C. M. (2022) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2022.103414 · Cited by 21
El-Toukhy, S. E., El‐Daly, S. M., Kamel, M. M., & Nabih, H. K. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04492-2 · Cited by 21
Sun, Y., Yu, H., Han, S., Ran, R., Yang, Y. Z., Tang, Y., Wang, Y., Zhang, W., Tang, H. Y., Fu, B., et al. (2023) · National Science Review · doi:10.1093/nsr/nwae022 · Cited by 21
Mayerhoefer, M. E., Kienzle, A., Woo, S., & Vargas, H. A. (2025) · Radiology · doi:10.1148/radiol.241030 · Cited by 19
Novel biomarkers for monitoring and management of hepatocellular carcinoma
Solhi, R., Pourhamzeh, M., Zarrabi, A., Hassan, M., Mirzaei, H., & Vosough, M. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03600-1 · Cited by 23
“At present, there is a lack of research on the practical significance of liquid biopsy for advanced HCC [100].”
Future Directions in the Use of SAbR for the Treatment of Oligometastatic Cancers
Morris, Z. S., Dohopolski, M. J., Rahimi, A. S., & Timmerman, R. D. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.03.004 · Cited by 19
Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?
Gong, X., Zhang, H., Liu, X., Liu, Y., Liu, J., Fapohunda, F. O., Lü, P., Wang, K., & Tang, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977999 · Cited by 19
“Liquid biopsy is defined by the National Cancer Institute (NCI) as “a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood or for pieces of DNA from tumor cells that are in the blood” (Underwood et al., 2020).”
BackgroundMicrotechnology-enabled filtration-based liquid biopsy: challenges and practical considerations
Liu, Y., Han, X., Li, T., & Wang, W. (2021) · Lab on a Chip · doi:10.1039/d0lc01101k · Cited by 18
Phosphorylated Proteins from Serum: A Promising Potential Diagnostic Biomarker of Cancer
Ghosh, R., Ahmed, R., Ahmed, H., & Chatterjee, B. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012359 · Cited by 14
“To confirm the imaging result, solid and liquid biopsies were done for different cancer biomarker tests by proteomic study in the majority of the cancer [59].”
MethodJardali, G., Lawrance, L., Dawi, L., Dupont, J., Gautier, O., Kind, M., Ammari, S., Hadchiti, J., Choucair, A., Bayle, A., et al. (2025) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2025.06.002 · Cited by 12
Noh, J. M., Kim, Y. J., Lee, H. Y., Choi, C., Ahn, W.-G., Lee, T., Pyo, H., Park, J. H., Park, D., & Park, W. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.151 · Cited by 12
“The shifting paradigm toward serially monitoring tumor molecular characteristics to more precisely guide therapy provides an opportunity for new diagnostic studies to determine the best way to acquire this information [13].”
Peptide-based optical biosensors: A promising approach for early-stage cancer detection
Soni, G. K., Saima, S., Manhas, P., & Sharma, R. K. (2022) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2022.100259 · Cited by 12
Jones, N., & NONAKA, T. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1339357 · Cited by 15
“Liquid biopsy remains less invasive than excisional biopsy or other test requiring intravenous contrast by requiring only access to a peripheral vein for a blood draw (Perakis and Speicher, 2017; Lianidou and Pantel, 2019; Underwood et al., 2020).”
BackgroundThe prospects and limitations of liquid biopsy utilization for clinical practice in Taiwan
Li, H.-Y., Chang, C.-C., Yang, Y.-H. S., Yao, C., Hsieh, C., & Chang, S.-H. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100290 · Cited by 11
“It is primarily utilized for analyzing circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA), which are released from the primary tumor into the bloodstream [1 – 3].”
Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer
Ghani, M. A., Liau, J., Eskander, R. N., Mell, L. K., Yusufaly, T., & Obrzut, S. L. (2022) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001358 · Cited by 11
The potential of CircRNA1002 as a biomarker in hepatitis B virus-related hepatocellular carcinoma
Li, Y., Li, R., Cheng, D., Fu, X., Fu, L., & Peng, S. (2022) · PeerJ · doi:10.7717/peerj.13640 · Cited by 11
“Cancer research has sought to verify the diagnostic and monitoring value of these liquid biopsy indicators (Underwood et al., 2020), especially in HCC (Qi et al.”
BackgroundCirculating nucleic acids as liquid biopsies for disease prediction, screening and diagnosis
Sun, Y., Tang, Y., Yu, L., Wang, Y., Peng, S., & Zhou, X. (2023) · Science China Chemistry · doi:10.1007/s11426-023-1727-9 · Cited by 10
Derderian, S., Vesval, Q., Wissing, M. D., Hamel, L., Côté, N., Vanhuyse, M., Ferrario, C., Bladou, F., Aprikian, A. G., & Chevalier, S. (2022) · Clinical and Translational Science · doi:10.1111/cts.13372 · Cited by 10
Whole-Body MRI in Children: Concepts and Controversies—AJR Expert Panel Narrative Review
Gallo-Bernal, S., Chan, S. S., Cho, Y. Y., Daldrup-Link, H. E., Gee, M. S., Kemp, J. M., Kraus, M. S., Meyers, A. B., von Krüchten, V. R., & Greer, M. C. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.24.32178 · Cited by 8
Yeung, J., Fotiadis, N., Διαμαντόπουλος, Α., Tutt, A. N. J., Roxanis, I., & Bandula, S. (2023) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2023.03.012 · Cited by 10
Optical biosensors for detection of exosomes
Vafadar, A., Maleki, M., Ehtiati, S., Moghadam, H. Z., & Savardashtaki, A. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120704 · Cited by 7
Jadhav, P. A., Pansare, K., Hole, A. R., Ingle, A., Govekar, R. B., & Krishna, C. M. (2022) · Journal of Raman Spectroscopy · doi:10.1002/jrs.6450 · Cited by 7
Liquid Biopsies in Colorectal Liver Metastases: Towards the Era of Precision Oncologic Surgery
Tsilimigras, D. I., Ntanasis‐Stathopoulos, I., & Pawlik, T. M. (2022) · Cancers · doi:10.3390/cancers14174237 · Cited by 6
“Indeterminate CT findings remain a significant challenge for oncologists and can often lead to delayed interventions [41].”
BackgroundJiang, Y., He, J., Wang, X., Liu, C., Zhou, W., Liu, D., Guo, Z., & Liu, K. (2023) · Platelets · doi:10.1080/09537104.2023.2212071 · Cited by 6
“8 Compared to tissue-based biopsies, liquid biopsies are less invasive, easy to access, convenient for serial tracking and better in eliminating intratumoral spatial heterogeneity.”
BackgroundJi, Y., Ju, Y., Kong, H., Xu, Y., Zhao, C., Zhang, R., Ma, Y., Zheng, L., Shi, L. R., Wu, A., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202505917 · Cited by 5
“Biopsies are restricted by anatomical accessibility and provide only a static snapshot of tumor evolution [1], while imaging often detects disease only after significant progression and provides limited molecular resolution [2].”
Jiang, W., Zhang, X., Xu, Z., Cheng, Q., Li, X., Zhu, Y., Lu, F., Dong, L., Zeng, L., Zhong, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202410713 · Cited by 6
Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine
Sone, M., Sugawara, S., & Yatabe, Y. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01271-7 · Cited by 5
Ha, S. M., Kim, H., Kim, Y., Noh, D., Han, W., & Chang, J. M. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06527-1 · Cited by 5
“In the era of precision medicine, understanding the utility of liquid biopsy will be necessary, and radiologists should provide more personalized management beyond imaging with liquid biopsy as another cost-effective mean of screening and diagnosis of breast cancer [19].”
BackgroundLin, Y., Bale, R. J., Brock, K. K., & Odisio, B. C. (2022) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1970245 · Cited by 5
“The liquid biopsy may provide serial monitoring of tumor heterogeneity and evolution over time and guiding clinical decisions [143].”
BackgroundJi, F., Chen, L., Chen, Z., Luo, B., Wang, Y., & Lan, X. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.853 · Cited by 6
Waldenmaier, M., Schulte, L.-A., Schönfelder, J., Fürstberger, A., Kraus, J. M., Daiß, N., Seibold, T., Morawe, M., Ettrich, T. J., Kestler, H. A., et al. (2022) · Cancers · doi:10.3390/cancers14041074 · Cited by 5
“In contrast, liquid biopsies are easy to obtain with low burden for patients and cause lower costs for the healthcare system [11,50].”
BackgroundTokaç, R. H., Tokac, E. C. B., Yararbaş, Ü., Aykut, A., Durmaz, A., Akın, H., & Argon, A. M. (2025) · Cancer Medicine · doi:10.1002/cam4.71049 · Cited by 4
“Our study suggests that integrating metabolic volumetric parameters with liquid biopsy in diagnostic, prognostic, and treat-ment response algorithms could enhance their effectiveness [27].”
Designing expanded and contracted porphyrin–azulene based photosensitizers for photodynamic therapy
Rajput, S. S., Razdan, S., Banana, T., Chandravanshi, N., & Alam, M. M. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp00154d · Cited by 4
Liquid biopsies in precision oncology for older adults with cancer
Zhao, Y., Herrera-Caceres, J. O., Nobes, J. H., Lyu, Z., Vetter, M. H. F., Falandry, C., Goede, V., Neuendorff, N. R., Loh, K. P., Canin, B. E., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01285-5 · Cited by 3
“Venipuncture is associated with lower rates of procedural complications and is generally more acceptable to patients compared with tissue biopsy, especially where repeat sampling may be required 15,16 .”
Goel, R., Satapathy, S., Chandekar, K. R., Ballal, S., Agarwal, S., Deo, S. S. V., Tripathi, M., & Bal, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1473262 · Cited by 3
Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles
Wu, X., Iliuk, A. B., & Tao, W. A. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.09.003 · Cited by 4
In‐silico selection of cancer blood plasma proteins by integrating genomic and proteomic databases
Chatterjee, G., Ferris, B., Momenbeitollahi, N., & Li, H. (2021) · PROTEOMICS · doi:10.1002/pmic.202100230 · Cited by 3
“a tissue biopsy, not risky, and could be available for all cancer types [1, 2].”
BackgroundThe oxidative stress-associated long non-coding RNAs in pancreatic cancer
Baradaran-Bagherian, S., Mohseni, M. M., Sharifi, R., Amirinejad, R., & Shirvani-Farsani, Z. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.04.006 · Cited by 2
Simultaneous detection of miR-21 and miR-155 using a multiplexed silicon nanowire FET biosensor
Yadlapalli, B. K., Wu, P.-J., Lee, Y.-H., & Chen, W.-Y. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.117657 · Cited by 2
Lee, T. H., Park, E., Goh, Y.-G., Lee, H. B., Rou, W. S., & Eun, H. S. (2021) · Micromachines · doi:10.3390/mi12080987 · Cited by 2
“Tumor markers, such as carbohydrate antigen 19-9 (CA19-9) or carcinoembryonic antigen (CEA), have widely been used for predicting a prognosis [2].”
MethodTumor Microenvironment and Epigenetic Implications in Breast Cancer Progression
Darbandi, M., & Bado, I. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-66686-5_2 · Cited by 3
Asker, N., & Gabal, R. A. (2022) · Trends in Sciences · doi:10.48048/tis.2023.3566 · Cited by 2
Liquid Biopsies: As an Emerging Tool in Cancer Diagnosis and Monitoring Therapies in Metastasis
Khade, O., Nagrekar, S., Parab, V., & Choubey, A. (2023) · Diseases & Research · doi:10.54457/dr.202301007 · Cited by 1
Ndacayisaba, L. J., Mason, J. M., & Kühn, P. (2023) · Current cancer research · doi:10.1007/978-3-031-22903-9_7 · Cited by 1
Screening for Breast Cancer: Imaging Updates
Bahl, M. (2026) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2026.01.003 · Cited by 1
Sharma, G., Jadhav, P. A., Banerjee, S., Gupta, D. P., Mahesh, P. A., Ganguly, K., Srivastava, S., & Krishna, C. M. (2025) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2025.103798 · Cited by 1
Serum Raman spectroscopy: Evaluation of tumour load variations in experimental carcinogenesis
Jadhav, P. A., Hole, A. R., Ingle, A., Govekar, R. B., Noothalapati, H., & Krishna, C. M. (2024) · Journal of Biophotonics · doi:10.1002/jbio.202300424 · Cited by 1
Goh, V. (2023) · Radiology · doi:10.1148/radiol.230223 · Cited by 1
Molecular Markers: Indispensable Tools for Diagnosing Central Nervous System Tumors
Szymańska, K., & Trubicka, J. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_155-1
Is er toekomstperspectief voor de ‘doctor’s doctor’? ofwel: Samen verder, ja gezellig!
Blickman, J. G. (2023) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2870-3_4
Dadadzhanov, D. R., Sapunova, A., Dadadzhanova, A. I., Alexan, G., & Vartanyan, T. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91765-0.00005-0
Genomic tools and techniques—An introduction
Ramanathan, B., Jadhav, S. A., Kumar, D. K., Ramsait, S. P., & Kumaramanickavel, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91799-5.00014-0
Liquid Biopsy and Imaging Are Complementary for Assessing Tumor Burden
Koh, D. (2024) · Radiology · doi:10.1148/radiol.242525
Xu, Y., Huang, B., Zhu, G., Chen, N. L., Yao, G., Wu, Z., Mo, L., & Liu, L. (2025) · Cancer Management and Research · doi:10.2147/cmar.s550357
Molecular Markers: Indispensable Tools for Diagnosing Central Nervous System Tumors
Szymańska, K., & Trubicka, J. (2025) · Springer eBooks · doi:10.1007/978-3-032-00763-6_155
Sheta, S. M., El‐Sheikh, S. M., Abo-Elfadl, M. T., Younis, A., Abd‐Elzaher, M. M., Othman, H., Strothmann, T., Fetzer, M. N. A., Boldog, I., & Janiak, C. (2025) · ChemMedChem · doi:10.1002/cmdc.202500665
Liu, Z., Tian, Y., Zhang, Z., Wu, L., Dong, L., & Xue, W. (2025) · Journal of Visualized Experiments · doi:10.3791/68708
Nanocontrasts, nanoprobes, and nanosensors in cancer diagnosis
Fatima, M., Saeed, L., & Riaz, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34671-2.00016-5
Microbiome and liquid biopsies
Afrose, R., & Amir, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40551-8.00021-4
Mujica, M. L., Boonkaew, S., Christensen, N. L., Pedersen, M. A., Jørgensen, K. R., Vendelbo, M. H., & Ferapontova, E. E. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03471-5
Liquid Biopsy in Cancer Monitoring: Beyond Circulating Tumor DNA
Ahmad, H., Ali, I., & Khadim, M. (2026) · Journal of Biomolecules Pathogenesis and Therapeutics · doi:10.68041/jbpt.v2i1/11 · Cited by 1
“Moreover, biological factors including clearance, fragmentation, and dilution of non-tumor cell-free DNA affect the reliable interpretation 9 .”
Metadata
- Authors
- Underwood, J. J., Quadri, R. S., Kalva, S. P., Shah, H., Sanjeeviah, A. R., Beg, M. S., & Sutphin, P. D.
- Affiliations
- University of North Texas Health Science Center (US)
- ORCID
- Venue
- Radiology
- Published
- 2020-01
- Volume
- 294
- Issue
- 1
- Pages
- 5-17
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2990366580
- Cited by
- 87
- References
- 95
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 13 · 2023: 20 · 2022: 19 · 2021: 10 · 2020: 4
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Radiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- liquid biopsy, circulating tumor DNA, circulating tumor cells, cancer screening, cancer diagnosis, cancer surveillance, targeted therapy, treatment resistance, molecular profiling, precision medicine, image-guided interventions, non-invasive diagnosis
- MeSH terms
- Liquid Biopsy, Humans, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.